ArticleBlood neoplasia2026
Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myeloma.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cell-based therapies of autoimmune diseases in the context of artificial intelligence development.Clinical and experimental medicine · 2026Review
- A 3D engineered multiple myeloma niche for evaluating CAR T cell therapy.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the mechanisms that drive chimeric antigen receptor (CAR) T-cell function and persistence in multiple myeloma (MM) remains a critical challenge for improving therapeutic outcomes. In this study, we applied single-cell multiomics and gene regulatory network analysis to characterize the transcriptional dynamics and clonal evolution of B-cell maturation antigen-targeted CAR T-cells in longitudinally collected bone marrow (BM) and peripheral blood (PB) samples from patients with MM. Our results revealed that CAR T cells infiltrating BM exhibited a more activated and exhausted phenotype than their PB counterparts, with key transcriptional regulators driving these changes. Dysregulation in the effector-to-memory transition led to increased presence of terminally differentiated CAR T-cells, correlating with poor persistence. Additionally, we identified a hyperexpanded CAR T-cell clone in the BM of a patient in partial response, marked by elevated interleukin-10 (IL-10) expression. Functional analyses demonstrated that stimulation of endogenous T-cell receptor (TCR) enhanced IL-10 production, potentially contributing to impaired CAR T-cell proliferation and persistence. These findings uncover regulatory mechanisms influencing CAR T-cell dynamics, offering new insights into improving CAR T-cell persistence and therapeutic efficacy in MM, and highlight potential molecular targets for optimizing CAR T-cell therapy in patients with MM.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.